Damora Therapeutics, Inc. DMRA
23.70 USD +1.84 (+8.42%)
At closeNov 6, 2026, 4:01 PM EST
23.70 0.00 0.00%
After hours · Nov 6, 4:01 PM ET
21.13 Day range 24.16
4.95 52-week range 34.14
- YTD
- +3.00%
- 1 year
- +307.22%
Financial health
Altman Z-Score
21.55 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
B-2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 5
- P/E 1
- P/B 5
Valuation
P/E -0.2×
FY 2018 5y median -0.5× FY 2025
P/S 0.0×
FY 2018 5y median 0.0× FY 2025
P/B 0.1×
FY 2018 5y median 0.5× FY 2025
P/FCF -4.7×
FY 2018 5y median -0.7× FY 2025
EV/EBITDA 1.1×
FY 2018 5y median 0.1× FY 2025
EV/Sales 0.0×
FY 2018 5y median 0.0× FY 2025
FCF Yield -21.4%
FY 2018 5y median -147.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2018 5y median 0.0% FY 2025
ROE -87.3%
FY 2018 5y median -99.8% FY 2025
ROIC -87.7%
FY 2018 5y median -97.8% FY 2025
ROA -80.5%
FY 2018 5y median -84.2% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2018 FY 2025
Operating Income -1148.0%
FY 2018 FY 2025
EPS (diluted) -725.6%
FY 2018 FY 2025
Free Cash Flow 63.9%
FY 2018 FY 2025
Financial Health
Current Ratio 13.0×
FY 2018 5y median 13.0× FY 2025
Quick Ratio 13.0×
FY 2018 5y median 13.0× FY 2025
Debt / Equity 0.0×
FY 2018 5y median 0.0× FY 2025
Net Debt / EBITDA 1.2×
FY 2018 5y median 0.6× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31